|
Title |
|
|
|
Importance of secondary screening with clinical isolates for anti-leishmania drug discovery
| |
Author |
|
|
|
| |
Abstract |
|
|
| | |
Language |
|
|
|
English
| |
Source (journal) |
|
|
|
Scientific reports. - London, 2011, currens | |
Publication |
|
|
|
London : Nature Publishing Group, 2018
| |
ISSN |
|
|
|
2045-2322
| |
Volume/pages |
|
|
|
8(2018), 13 p.
| |
Article Reference |
|
|
|
11765
| |
ISI |
|
|
|
000440782000052
| |
Pubmed ID |
|
|
|
30082744
| |
Medium |
|
|
|
E-only publicatie
| |
Full text (Publisher's DOI) |
|
|
| | |
Full text (open access) |
|
|
| | |
|
Faculty/Department |
|
|
| | |
Research group |
|
|
|
Project info |
|
|
|
EUROLEISH-NET: Control of leishmaniasis, from bench to bedside and community Targeting host-encoded factors for anti-leishmania therapy? Insights from chemical genetics and antimony resistant field isolates.
Publication type |
|
|
| | | |
Subject |
|
|
| | | |
Affiliation |
|
|
|
Publications with a UAntwerp address
| |
|
|
Identification |
|
| |
|
|
Creation |
|
| |
07.09.2018
|
|
Last edited |
|
| |
04.04.2021
|
|
To cite this reference |
|
|
| | |
|
| |